Anticancer Drugs Medicine Necitumumab Oncology Pharmacology Physiotherapy


In this article we will discuss Necitumumab
(Dosage Overview)

In this article, we will discuss Necitumumab (Dosage Overview). So, let’s get started.


Squamous Non-Small Cell Lung Cancer (NSCLC)
Necitumumab is indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.

Limitation of Use
Necitumumab is not indicated for treatment of non-squamous non-small cell lung cancer.


Recommended Dose and Schedule
The recommended dose of Necitumumab is 800 mg administered as an intravenous infusion over 60 minutes on Days 1 and 8 of each 3-week cycle prior to gemcitabine and cisplatin infusion. Continue Necitumumab until disease progression or unacceptable toxicity.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.